Onconova Therapeutics Inc. Presents Clinical Trial Data for Oral Rigosertib at American Society of Clinical Oncology Annual Meeting
NEWTOWN, Pa. & PENNINGTON, N.J.--(BUSINESS WIRE)--Onconova Therapeutics, Inc. announced that two presentations regarding the development of an oral formulation of rigosertib (Estybon®, ON 01910.Na) for patients with solid tumors and myelodysplastic syndromes (MDS) will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-5, in Chicago, Illinois.